Results 201 to 210 of about 458,390 (288)
ABSTRACT Objective Malignant gliomas pose significant therapeutic challenges. This study aimed to identify and characterize a novel chimeric RNA in glioma and assess its clinical and functional significance for precision treatment. Methods The C19orf47‐AKT2 chimeric RNAs were identified through RNA sequencing and validated by polymerase chain reaction.
Zihan Wang+11 more
wiley +1 more source
Social exclusion: differences in neural mechanisms underlying direct versus vicarious experience. [PDF]
Song J, Lian T, Zhang Y, Cao M, Jiao Z.
europepmc +1 more source
In Vitro Modeling of Natural Killer Cell Cytotoxicity to Inform Personalized ALS Therapeutics
ABSTRACT Objective Natural killer (NK) cells might contribute to motor neuron death in amyotrophic lateral sclerosis (ALS) through direct cytotoxicity, a process that could be inhibited with the FDA‐approved JAK/STAT pathway inhibitor, tofacitinib. This study aimed to verify that tofacitinib can suppress NK cell cytotoxicity, investigate if immune cell
Benjamin J. Murdock+8 more
wiley +1 more source
Syndemics in women's health: poverty, social exclusion, and clustering of thrombotic and hemostasis disorders. [PDF]
O'Rourke E, Kelliher S, Kevane B.
europepmc +1 more source
A Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral Sclerosis
ABSTRACT Severe weight loss in amyotrophic lateral sclerosis (ALS) is common, multifactorial, and associated with shortened survival. Using longitudinal weight data from over 6000 patients with ALS across three cohorts, we built an accelerated failure time model to predict the risk of future severe (≥ 10%) weight loss using five single‐timepoint ...
David G. Lester+4 more
wiley +1 more source
Effects of Social Exclusion on Self-Evaluation: Domain Discrepancy Based on the Big Two Model. [PDF]
Zhang C+5 more
europepmc +1 more source
Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis
ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji+9 more
wiley +1 more source
Here Comes Revenge: Peer Victimization Relates to Neural and Behavioral Responses to Social Exclusion. [PDF]
Kellij S+4 more
europepmc +1 more source
ABSTRACT Objective To evaluate the long‐term impact of early intensive treatment (EIT) versus escalation (ESC) strategies using high‐efficacy disease‐modifying therapies (HE‐DMTs) on disability progression in relapsing multiple sclerosis (RMS). Methods This observational study included 4878 RMS patients from the Italian Multiple Sclerosis Register ...
Pietro Iaffaldano+47 more
wiley +1 more source